OCULIS
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
OCULIS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2003-01-01
Address:
Reykjavík, Gullbringusysla, Iceland
Country:
Iceland
Website Url:
http://www.oculis.com
Total Employee:
11+
Status:
Active
Contact:
+354 546-4440
Email Addresses:
[email protected]
Total Funding:
94.36 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hyfinity Investments
Hyfinity Investments investment in Series C - Oculis
Bay City Capital
Bay City Capital investment in Series C - Oculis
Nan Fung Life Sciences
Nan Fung Life Sciences investment in Series C - Oculis
BVCF
BVCF investment in Series C - Oculis
Tekla Capital Management
Tekla Capital Management investment in Series C - Oculis
Silfurberg
Silfurberg investment in Series C - Oculis
Brunnur Ventures
Brunnur Ventures investment in Series C - Oculis
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series C - Oculis
VI Partners
VI Partners investment in Series C - Oculis
Novartis Venture Fund
Novartis Venture Fund investment in Series C - Oculis
Key Employee Changes
Official Site Inspections
http://www.oculis.com Semrush global rank: 3.27 M Semrush visits lastest month: 5.03 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Oculis"
Oculis | Investors and Media
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple …See details»
About Us - Ophthalmology Companies - Oculis
Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. We are driven by patients suffering from eye diseases to develop transformative innovations that have the potential to address …See details»
Meet Our Team - Oculis
We are a global biopharmaceutical company purposefully driven to save sight and improve eye care. Led by an experienced management team and supported by leading investors and …See details»
Oculis - Crunchbase Company Profile & Funding
The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive …See details»
Oculis | Corporate Governance
The Board of Directors of Oculis Holding AG (the “Company”) sets high standards for our employees, officers and directors. Implicit in this philosophy is the importance of sound …See details»
Oculis Holding - Overview, News & Similar companies - ZoomInfo
Aug 12, 2024 Who is Oculis Holding. Headquartered in Zug, Switzerland with global operations in Europe, the U.S. and China. Oculis is a biopharmaceutical company focused on developing …See details»
Oculis | European Clinical Trials Information Network
Oculis is a Swiss-based biopharmaceutical company that specializes in developing innovative treatments for ocular diseases. Founded in 2003, the company has a rich history of pioneering …See details»
Oculis Holding Company Profile 2024: Stock …
Oculis Holding General Information Description. Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular …See details»
Oculis Operations Sàrl – Swiss Biotech
Oculis is a biopharmaceutical company purposefully driven to save sight & improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in …See details»
Oculis Company Profile - Office Locations, Competitors, Revenue …
Oculis is a biopharmaceutical company focused on eye care. Its products include OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for …See details»
Oculis - Org Chart, Teams, Culture & Jobs - The Org
Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back-and front-of-the-eye in order to …See details»
FAQs - Oculis
Continental Stock Transfer & Trust Company 1 State Street, 30th Floor New York, New York 10004. For help with change of address, transfer of shares, loss of share certificates, …See details»
Oculis Reports Q3 2024 Financial Results and Provides Company …
Nov 7, 2024 Merger and listing expense, which was a one-time non-cash expense CHF 34.9 million or $38.2 million in total operating expenses in the nine months ended September 30, …See details»
Our Culture: Mission To Save Sight & Improve Eye Care- Oculis
At Oculis, we believe that a thriving culture is an essential component of our success. We are committed to creating and fostering a positive environment where our employees can bring …See details»
Oculis | Oculis Announces Completion of Enrollment in Phase 2 ...
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully …See details»
Oculis: Vision for a Paradigm Shift in Ophthalmology Delivery
Aug 11, 2021 Oculis’ second asset, OCS-02, is currently in Phase II. This is a first-in-class anti-TNFα antibody in-licenced from Novartis, and based on a proprietary single-chain antibody …See details»
Oculis | CAREERS
Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to …See details»
Rethinking Ophthalmology - Oculis
Aug 8, 2023 Oculis announces positive top line results from DIAMOND Stage 1 phase 3 trial in diabetic macular edema with OCS-01 eye drops. .May 22, 2023. 3. Shulman S, et al. Acta …See details»
Ophthalmic Eye Drops For Dry Eyes Treatment - Oculis
Explore Oculis Ophthalmic Eye Drops For Dry Eyes Treatment. Skip to content. Contact Us; Join Us; Linkedin; Submit Search. Our Company. About Us; Governance; Our Culture; Our …See details»